Key Highlights
- FibroBiologics (NASDAQ: FBLG) named Kathleen Rubins, Ph.D. To its board on July 8, 2026, following Matt Link’s resignation.
- Rubins, a former NASA astronaut with over a decade of service, will serve until the 2029 annual stockholder meeting.
- The appointment includes roles on the Audit, Compensation, and Governance and Nominating committees, with compensation aligned to the company’s non-employee director policy.
- Rubins’ background includes advanced research in microbiology and infectious diseases, along with military service in the U.S. Army Reserve.
Leadership Shift at FibroBiologics
FibroBiologics (NASDAQ: FBLG) announced a change in its board composition, appointing Kathleen Rubins, Ph.D. As a director following the resignation of Matt Link. The appointment underscores the company’s commitment to integrating expertise in biomedical research and space-related scientific advancements into its governance structure.
New Director’s Background
Rubins brings a distinguished career to FibroBiologics, having served as a NASA astronaut from 2009 until her recent departure. Prior to her time at NASA, she contributed to scientific research in infectious diseases and molecular biology, areas of growing relevance to the biotech sector.
Board Role and Committees
The appointment, effective July 8, 2026, designates Rubins as a Class III director with a term extending to the 2029 annual stockholder meeting. She will serve on the Audit, Compensation, and Governance and Nominating committees, where her insights will support financial oversight, executive compensation strategies, and corporate governance practices.
Compensation and Indemnification
Rubins will receive compensation in accordance with FibroBiologics’ Non-Employee Director Compensation Policy.
Military and Professional Affiliations
In addition to her NASA career, Rubins holds a position as a Major in the U.S. Army Reserve Innovation Command, where she focuses on technological and scientific innovation. Her dual roles in space exploration and military research highlight her ability to navigate complex, high-stakes environments, a skill set that may prove valuable for FibroBiologics as it advances its pipeline in regenerative medicine.
No Conflicts of Interest
The company’s filing confirms that Rubins has no material transactions with FibroBiologics that would require disclosure under Regulation S-K. Her appointment was made independently of any prior agreements, ensuring her ability to serve the board without conflicts.
Timeline of Changes
Matt Link’s resignation became effective on July 2, 2026, and Rubins was appointed to the board six days later. The rapid transition reflects the board’s proactive efforts to maintain strong governance and leadership continuity during this period.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...